IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces a class action lawsuit against Aratana Therapeutics, Inc. (“Aratana” or the “Company”) (Nasdaq: PETX). Investors who purchased or otherwise acquired shares between March 16, 2015 and February 3, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the April 7, 2017 lead plaintiff motion deadline.
If you purchased shares of Aratana during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at email@example.com.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The Complaint states that throughout the Class Period, Aratana made false and/or misleading statements and/or failed to disclose: that the Company did not have manufacturing contracts in place sufficient to support manufacturing of its appetite stimulation drug ENTYCE at a commercial scale; ENTYCE was not likely to be commercially available until late 2017; the Company had misled investors with respect to the likely timeline for a commercial launch of ENTYCE; and that as a result of the above, Aratana’s public statements were materially false and misleading at all relevant times.
On February 6, 2017, the Company disclosed that the Center for Veterinary Medicine requested more information about ENTYCE. Aratana told investors that it “now anticipates that ENTYCE … will be commercially available by late 2017” and that the CVM's demand was “in connection with the Company's post-approval supplement request to transfer the manufacturing of ENTYCE to a new vendor in order to produce ENTYCE at a commercial scale.”
If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.